Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanitá, Rome, Italy.
Forensic Sci Int. 2010 Mar 20;196(1-3):59-63. doi: 10.1016/j.forsciint.2009.12.038. Epub 2010 Jan 21.
Methylphenidate (MPH) is a stimulant medication widely used for treating attention-deficit hyperactivity disorder (ADHD) in children and adolescents. Therapeutic monitoring for this drug is essentially lacking and alternative biological matrices, such as oral fluid and sweat, should be investigated for noninvasive assessment of short- and long-term history of drug use. We report the excretion profile of MHP and its metabolite ritalinic acid (RA) in oral fluid and sweat from a 12-year-old boy treated with the extended release drug formulation. Concentrations of MPH and RA in oral fluid, sweat and plasma were measured by liquid chromatography-mass spectrometry. Oral fluid-to-plasma ratio at each time interval was calculated at the start of the treatment and correlated with salivary pH. Excretion of MPH in sweat patches, collected up to 24h with PharmChek patches was also investigated. MPH and RA were both detected in oral fluid with a pharmacokinetic profile similar to that in plasma. Oral fluid peak concentrations of MPH ranged between 13.5 and 30.9 ng/mL at 3.0 h after drug intake. Oral fluid-to-plasma MPH ratio between 13.1 and 3.2 demonstrated an accumulation of the drug in oral fluid. Conversely, RA was found in oral fluid at peak concentration (23.4-62.9 ng/mL) equivalent to one-tenth of those found in plasma. Concentration profiles of MPH and RA in oral fluid were quite constant during the four weeks of drug administration. In sweat, MPH was detected for the first time at 5h after drug administration (range: 9.3-11.2 ng/patch) up to 24h (range: 29.8-38.7 ng/patch). RA was not detected in the sweat patches during the 24h time of collection. The results suggest that measurement of MPH in oral fluid can be used as a potential alternative to drug monitoring in plasma. Moreover, MPH measurement in sweat patches can be used for noninvasive monitoring of MPH consumption and misuse in situations where detection of recent abuse is of interest.
哌醋甲酯(MPH)是一种兴奋剂药物,广泛用于治疗儿童和青少年的注意力缺陷多动障碍(ADHD)。该药物的治疗监测实际上是缺乏的,应该研究替代的生物基质,如口腔液和汗液,用于非侵入性评估药物使用的短期和长期历史。我们报告了一种 12 岁男孩使用延长释放药物制剂治疗时口腔液和汗液中 MPH 和其代谢物利托那酸(RA)的排泄情况。通过液相色谱-质谱法测量口腔液、汗液和血浆中的 MPH 和 RA 浓度。在治疗开始时计算每个时间间隔的口腔液与血浆比值,并与唾液 pH 值相关。还研究了 PharmChek 贴剂收集的长达 24 小时的汗液贴片的 MPH 排泄情况。在口腔液中检测到 MPH 和 RA,其药代动力学特征与血浆相似。MPH 的口腔液峰浓度在药物摄入后 3.0 小时为 13.5 至 30.9ng/mL。MPH 的口腔液-血浆比在 13.1 至 3.2 之间,表明药物在口腔液中积累。相反,RA 在口腔液中的浓度(23.4-62.9ng/mL)相当于其在血浆中的十分之一。在药物给药的四周期间,MPH 和 RA 在口腔液中的浓度曲线相当稳定。在汗液中,MPH 首次在药物给药后 5 小时检测到(范围:9.3-11.2ng/贴),直到 24 小时(范围:29.8-38.7ng/贴)。在 24 小时的收集时间内,RA 未在汗液贴片上检测到。结果表明,口腔液中 MPH 的测量可作为血浆药物监测的潜在替代方法。此外,在需要检测近期滥用情况的情况下,汗液贴片上的 MPH 测量可用于非侵入性监测 MPH 的使用和滥用情况。